adverse effects

In early 2011, clinical trials of ACE-031, a myostatin inhibitor, were halted pending resolution of safety issues; in May 2013, the developers discontinued work on the drug

posted on May 2, 2013 - 12:00pm

New content is being added every day. Please check back again.